To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson’s disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
Bead-Conjugated TMEM192 Antibody (Ms)
Antibody
Magnetic bead-conjugated rabbit monoclonal antibody directed against mouse TMEM192 for immunoprecipitation of lysosomes. An unconjugated version of this antibody is also available. This antibody was generated by Dr. Dario Alessi at the University of Dundee and deposited through the MJFF Sponsored Tools Program as part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
CLN3 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including
-Knockout (homozygous)
-R334H (heterozygous and homozygous) - in development, est Q3 2026
-V330I (heterozygous and homozygous) - in development, est Q3 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
PSMF1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PSMF1, including
- -R231* (heterozygous and homozygous) - in development, est Q3 2026
- -R242C (heterozygous and homozygous) - in development, est Q3 2026
- -Knockout (homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
SMPD1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SMPD1, including
- -Q294K (heterozygous and homozygous) - in development, est Q3 2026
- -L262Rfs*s (heterozygous and homozygous) - in development, est Q3 2026
- -Knockout (homozygous)
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
GALC Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GALC, including
-Knockout (homozygous)
-R101X (heterozygous and homozygous) - in development, est Q3 2026
-Y541S (heterozygous and homozygous) - in development, est Q3 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
MHC-I H2-D & H2-K Antibody
Antibody
Rabbit monoclonal antibody directed against mouse MHC-I H2-D and H2-K for immunoblotting and immunostaining applications. This antibody cross-reacts with H2-D: (D-B, D-D, H-2 class I histocompatibility antigen, alpha chain, D-P, D-K), H2-K: (K-B, K-D, K-K, K-Q, K-W28 alpha chain)], H2-L, H2-Q10, H2-Q8, H2-Q7, PH-2D-2.
This antibody development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative.
VPS13C Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in VPS13C, including
- -R117* (heterozygous and homozygous) - in development, est late 2025
- -G1389R (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
D1-Cre Mouse*
Mouse Model
D1-Cre knock-in express Cre recombinase from the mouse Drd1 promoter and enable the targeting of Drd1-expressing cells and the direct pathway spiny projection neuronal (dSPN) subpopulation of neurons in the striatum. Model was generated and deposited by Dr. Rui Costa at Allen Institute through the MJFF Sponsored Tools Program, and supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
D1-Flp Mouse*
Mouse Model
D1-FlpO knock-in expresses optimized Flp recombinase (FlpO) from the mouse Drd1 promoter and enables the targeting of Drd1-expressing cells and the direct pathway spiny projection neuronal (dSPN) subpopulation of neurons in the striatum. Model was generated and deposited by Dr. Rui Costa at Allen Institute through the MJFF Sponsored Tools Program, and supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
A2a-Cre Mouse*
Mouse Model
A2a-Cre knock-in mice express Cre recombinase from the mouse Adora2a promoter and enable the targeting of Adora2a-expressing cells and the indirect pathway spiny projection neuronal (iSPN) subpopulation of neurons in the striatum. Model was generated and deposited by Dr. Rui Costa at Allen Institute through the MJFF Sponsored Tools Program, and supported by the Aligning Science Across Parkinson’s (ASAP) Initiative.
Have questions or need additional information?
Email [email protected] with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic